Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview

Published: June 2015
No. of Pages: 208
   

Available to Insight Pharma Reports is Ocular Disorders: Rising Therapeutics, Technologies, and Devices Report. This report begins with outlining Age-related macular degeneration (both wet and dry) and delving into Anti-VEGF therapies in chapter 2. Further providing substantial weight to this report, several companies were interviewed on their approach to targeting wet and dry AMD, their strategies for seeking alternative therapeutic options, and the hardships they have encountered in their research and product execution.

Report highlights include:  

  • Exclusive interviews from four companies (Oraya Therapeutics, VisionCare Ophthalmic Technologies, Omeros, and Kala Pharmaceuticals) providing details of their products.
  • Both invasive and noninvasive procedures are discussed, along with current treatment options and how they relate to rising therapies.
  • Demographic survey and analysis of researchers working in ocular disorders including promising therapeutic options, targets of interest, and challenges encountered.
  • Over 250 companies featuring clinical trials and pipeline data.
  • Over 200 company and institution profiles included

Who has already purchased?

Allied Minds Inc, Astellas Pharma Inc, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Bioptigen Inc, Dyax Corp, Fraunhofer IME, KIST, MorphoSys AG, PharmaQuest Assoc, Roche Pharma, Shire Human Genetic Therapies, SOBI  

Executive Summary

New to Insight Pharma Reports is: Ocular Disorders: Rising Therapeutics, Technologies, and Devices. This report covers several companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications. In an interview with several companies including Oraya Therapeutics, VisionCare Ophthalmic Technologies, Omeros, and Kala Pharmaceuticals, representatives mentioned several technologies and devices in development to improve the current line of therapeutics.

Both invasive and noninvasive procedures are discussed, along with current treatment options and how they relate to rising therapies. Specific highlights of this report include extensive research, company backgrounds, challenges, and validation techniques for therapeutic applications offered by the participating companies. These techniques include:

  • Radiation therapy
  • Implantable telescope technology
  • PharmacoSurgery
  • Mucosal penetrating products

Also available are complementary interviews with company representatives at the end of each section. The interviewees include:

  • President and CEO of Oraya Therapeutics
  • Marketing Director of VisionCare Ophthalmic Technologies
  • Chairman and CEO of Omeros
  • CMO of Kala Pharmaceuticals

Also included in this report is a demographic survey of researchers working in ocular disorders. Some of the concepts include ocular areas of research, promising therapeutic options, targets of interest, and challenges encountered.

Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview

Table of Contents

Executive Summary

Chapter 1: Age-Related Macular Degeneration
Wet AMD
Dry AMD

Chapter 2: Therapeutic Efficacy
Anti-VEGF therapies
Pegaptanib
Bevacizumab
Ranibizumab
VEGF Trap-EYE

Chapter 3: Oraya Therapeutics
Radiotherapy platform
Automatic Positioning System (APS)
I-Guide
System software
Radiation dosing
Potential complications and risk factors
Competitive advantage
Challenges and areas of improvement
Future expectations
Interview with Jim Taylor
Radiation therapy
Competitive advantage
Challenges encountered
Areas of improvement
Future expectations

Chapter 4: VisionCare Ophthalmic Technologies
Company background
Telescope technology
Complications and challenges
Interview with Reena Mishra
Company background
Telescope technology
Competitive advantage
Complications and challenges

Chapter 5: Omeros
Company background
PharmacoSurgery platform
Pipeline
Competitive advantage
Challenges encountered
Validation
Future expectations
Interview with Greg Demopulos
Company background
PharmacoSurgery platform
OMS302
Competitive advantage
Challenges encountered
Validation procedure
Future expectations

Chapter 6: Kala Pharmaceuticals
Company background
Mucosal penetrating products (MPP)
Competitive advantage
Future endeavors
Interview with Kim Brazzell
Company background
Mucosal penetrating products (MPP)
Challenges encountered
Competitive advantage
Future endeavor

Chapter 7: Platforms and Products

Chapter 8: Survey of Ocular Industry
Areas of development
Promising targets and therapies
Challenges encountered

Chapter 9: Clinical Trials and Pipeline Data

Chapter 10
Company Profiles 79
13therapeutics, Inc. 79
2C Tech Corporation, Inc. 79
AbbVie Inc. 80
Abdi Ìbrahim Ìlac Sanayi ve Tic A.S. (Abdi Ibrahim) 80
AC Immune SA 80
ACADIA Pharmaceuticals 80
Aciex Therapeutics, Inc. 81
Aciont Inc. 81
Acorn Biomedical, Inc. 81
Actavis hf. 82
Acucela Inc. 82
Adamed Sp. z o.o. 82
Adenovir Pharma AB 83
AdeTherapeutics Inc. 83
Aerie Pharmaceuticals, Inc. 83
Aerpio Therapeutics, Inc. 84
Akebia Therapeutics, Inc. 84
Akorn Pharmaceuticals, Inc. 84
Alcon Laboratories, Inc. 85
Alexion Pharmaceuticals, Inc. Translational Medicine Center 85
Alimera Sciences, Inc. 85
Alkeus Pharmaceuticals, Inc. 86
Allegro Ophthalmics LLC 86
Allergan, Inc. 86
Allergan S.A.U. 87
Altacor 87
Altheos, Inc. 87
Amakem Therapeutics NV 88
AmorChem L.P. 88
AngioLab, Inc. 88
Ångstrom Pharmaceuticals, Inc. 89
Apellis Pharmaceuticals, Inc. 89
Apitope International NV 89
Applied Genetic Technologies Corp. (AGTC) 90
ArcticDx, Inc. 90
Argos Therapeutics, Inc. 90
AriBio 91
Ascendis Pharma A/S 91
AsclepiX Therapeutics, LLC 91
Asklepios BioPharmaceutical, Inc. 92
Aspireo Pharmaceuticals Limited 92
Aus Bio Limited 92
Auven Therapeutics Management L.L.L.P. 93
Avalanche Biotechnologies, Inc. 93
Avedro 93
Axxam S.p.A. 94
Bach Pharma, Inc. 94
Bausch & Lomb 94
Bausch & Lomb Canada Inc. 95
Bayer Yakuhin, Ltd. 95
BCN Peptides S.A. 95
Beijing Northland Biotech Co., Ltd. 96
Beijing Tide Pharmaceutical Co., Ltd. 96
Benitec Biopharma Ltd. 96
Betastem Therapeutics, Inc. 97
Bicycle Therapeutics Limited 97
Binex Co., Ltd. 97
Biocodex S.A. 98
Biocycive 98
BioDiem Ltd 98
Bioftalmik 99
BioMotiv LLC 99
Bionure 99
Biophytis 100
Bloomage BioTechnology Corporation Limited 100
BluBio (Yantai) Biopharmaceutical Co., Ltd. 100
Bohus BioTech AB 101
Boston Children’s Hospital 101
Brill Pharma 101
Calista Therapeutics, Inc. 102
Can-Fite BioPharma Ltd. 102
Catalyst Biosciences 102
Cell Cure Neurosciences Ltd 103
CellSeed Inc. 103
Celsus Therapeutics plc 103
Celtaxsys, Inc. 103
Charlesson LLC 104
Chia Tai Tianquing Pharmaceutical Group Co., Ltd 104
China Resources Zizhu Pharmaceutical Co., Ltd 104
Circadian Technologies Limited 105
Clayton Biotechnologies, Inc. 105
Clearside Biomedical, Inc. 105
Compugen Ltd. 106
Corena Therapeutics SARL 106
D.Western Therapeutics Institute, Inc. 107
Dalian Innobioactives Co., Ltd. 107
Diaxonhit Therapeutics 107
DIOPTIC Laboratories, Inc. 107
DNAVEC Corporation 108
Dompé s.p.a. 108
Dong-A ST 108
Eleven Biotherapeutics, Inc. 109
Eli Lilly and Company 109
Emcure Pharmaceuticals Ltd. 109
Encore Vision, Inc. 109
Envisia Therapeutics™, Inc. 110
Enzo Biochem, Inc. 110
Eos Neuroscience, Inc. 110
EryDel S.p.A. 111
ESBATech, a Novartis company 111
Essex Bio-Technology Limited 111
Esteve 111
Eupraxia Pharmaceuticals Inc. 112
Europharm Laboratoires Co. Ltd. 112
Evonik Corporation 112
Exonate 113
EyeGate Pharmaceuticals, Inc. 113
EyeGene, Inc. 113
EyeTechCare SA 113
Eye Therapies LLC 114
Eyevensys SA 114
F. Hoffmann-La Roche AG 114
Farmaprojects S.A.U. 115
Farmigea S.p.A. 115
FirstString Research, Inc. 115
Foamix Pharmaceuticals Ltd. 115
Fondazione Telethon 116
ForSight Labs, LLC 116
ForSight VISION5, Inc. 116
Freedom Meditech, Inc. 117
La Fundación General de la Universidad de Valladolid FGUVa 117
Galecto Biotech AB 117
Genable Technologies Ltd. 117
Genentech, Inc. 118
Gene Signal International SA 118
GenSight Biologics 118
Genzyme® Corporation 119
GlaxoSmithKline plc 119
GrayBug® LLC 119
Griffin Discoveries BV 120
G-treeBNT Co., Ltd. 120
HanAll BioPharma Co. Ltd. 120
Hanlim Pharmaceuticals Inc. 120
Harmonic Pharma 121
Healios KK 121
Hemera Biosciences, Inc. 121
Herantis Pharma plc 122
High Point Pharmaceuticals, LLC (formerly TransTech Pharma, Inc.) 122
Horus Pharma 122
Hubei Kangzheng Pharmaceutical Co., Ltd. 122
Hyundai Pharm. Ind. Co., Ltd. 123
iCo Therapeutics Inc. 123
Iconic Therapeutics, Inc. 123
Ilsung Pharmaceuticals Co. Ltd. 124
Imagen Biotech, Inc. 124
Immco Diagnostics, Inc. 124
Immunservice GmbH 124
Implandata Ophthalmic Products GmbH 125
Imprimis Pharmaceuticals, Inc. 125
Inflamalps SA 125
InFlectis BioScience 126
InnoCore Technologies BV 126
InnoPharma, Inc. 126
Innovent Biologics, Inc. 127
Inotek Pharmaceuticals Corporation 127
InSite Vision Incorporated 128
Intellect Neurosciences, Inc. 128
InteRNA Technologies B.V. 128
International Stem Cell Corporation 128
Intrexon Corporation 129
ipal GmbH 129
Isis Pharmaceuticals, Inc. 129
iSTAR Medical SA 130
Jade Therapeutics, Inc. 130
Jiangsu Farever Pharmaceutical Co., Ltd. 130
Jiangsu T-mab BioPharma 130
Kala Pharmaceuticals, Inc. 131
KalVista Pharmaceuticals Ltd. 131
Kangmei Pharmaceutical Co., Ltd. 131
Korea Research Institute of Chemical Technology 132
Kowa Company, Ltd. 132
Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. 132
Kytogenics Pharmaceuticals, Inc. 132
Laboratoires Genévrier 133
Laboratoires Théa 133
Laboratorios SALVAT S.A. 133
Laboratorios Sophia S.A. de C.V. 133
Lacerta Bio Inc. 133
LambdaVision, Inc. 134
Lee’s Pharmaceutical Holdings Ltd. 134
Lexicon Pharmaceuticals, Inc. 134
Livwel Therapeutics, Inc. 135
Lotus Innovative Health, Ltd. 135
Lpath Incorporated 135
MacuCLEAR, Inc. 135
MacuLogix, Inc. 136
Mati Therapeutics, Inc. 136
Merck Serono (EMD Serono) 136
Mesoblast Limited 137
Meta-IQ 137
Mimetogen Pharmaceuticals, Inc. 137
Mitsubishi Tanabe Pharma Corporation 137
Molecular Partners AG 138
Montefarmaco OTC S.p.A. 138
Moorfields Pharmaceuticals 138
Mystic Pharmaceuticals 138
Myungmoon Pharm. Co., Ltd. 139
Nanomerics 139
Nano Retina, Inc. 139
NanoVector srl 140
NanoViricides, Inc. 140
Nektar Therapeutics 140
NEMUS Bioscience, Inc. 140
Neothetics™, Inc. 141
Neuroptis Biotech 141
Neuroscienze PharmaNess S.c.a.r.L. 141
Neurotech Pharmaceuticals, Inc. 141
Nexus Pharamaceuticals, Inc. 142
NicOx Research Institute SRL 142
NicOx S.A. 142
NightstaRx Ltd. 142
NovaBay Pharmaceuticals, Inc. 143
Novaliq GmbH 143
NovaMedica LLC 143
Novartis International AG 144
Novartis Ophthalmics AG 144
NovelMed Therapeutics, Inc. 144
Ocata Therapeutics, Inc. 145
Ocugen, Inc. 145
Oculeve 145
Oculis ehf 146
Ogenx Therapeutics Corporation, Inc. 146
Ohr Pharmaceutical Inc. 146
Omeros Corporation 146
OMIDA AG 147
ONL Therapeutics LLC 147
OphthaliX, Inc. 147
OphthalmoPharma Ltd. 147
Ophthotech Corp. 148
Opocrin S.p.A. 148
Opthea Pty Ltd 148
Ora Bio Ltd. 149
Oraya Therapeutics, Inc. 149
Otsuka Pharmaceutical Europe Ltd 149
Oxford BioMedica plc 149
OxiGENE, Inc. 150
Palobiofarma S.L 150
Panoptes Pharma GmbH 150
PanOptica, Inc. 150
Parion Sciences 151
PDL BioPharma, Inc. 151
Perrigo Company plc 151
Pfenex Inc. 152
Pfizer 152
Pharma Two B Ltd. 153
Physica Pharma 153
Pieris Pharmaceuticals, Inc. 153
Pierre Fabre SA 154
PIQUR Therapeutics AG 154
Pixium Vision SA 154
PolyActiva Pty Ltd. 155
Potentia Pharmaceuticals, Inc. 155
Present Value Ltd 155
Promedior, Inc. 155
ProRetina Therapeutics, S.L. 156
Provectus Biopharmaceuticals, Inc. 156
pSivida Corp. 156
QLT Inc 157
Quark Pharmaceuticals, Inc. 157
Rapid Pathogen Screening, Inc. 157
Reata Pharmaceuticals, Inc. 158
Regeneron Pharmaceuticals 158
RegeneRx Biopharmaceuticals, Inc. 158
REGENXBIO Inc. 159
ReNeuron Group plc 159
Resolvyx Pharmaceuticals, Inc. 159
RestorGenex Corporation 160
RetroSense Therapeutics LLC 160
Rigel Pharmaceuticals, Inc. 160
River Vision Development Corp. 161
Roche Diagnostics GmbH 161
Roche SAS 161
R-Tech Ueno, Ltd. 161
RXi Pharmaceuticals Corporation 161
Sam Chun Dang Pharm. Co., Ltd 162
Samil Pharm. Co., Ltd. 162
SanBio, Inc. 162
Sanitas AB 162
Sanofi S.A. 163
Santen Pharmaceutical Co., Ltd. 163
Santhera Pharmaceuticals 163
SATT Lutech 164
SCYNEXIS, Inc. 164
Senju Pharmaceutical Co., Ltd 164
Shire plc 165
SIFI SpA 165
Silvanols 165
Sirnaomics, Inc. 166
SK Biopharmaceuticals 166
Solx, Inc. 166
Spark Therapeutics, Inc. 167
Specialised Therapeutics Australia Pty Ltd 167
Starpharma 167
Stealth Peptides International (Shanghai) Inc. 168
Stelic Institute & Co., Inc. 168
Stelis Biopharma Pvt. Ltd. 168
StemCells, Inc. 169
Strathclyde University, Health Technologies 169
Streuli Pharma AG 169
Strides Arcolab Ltd. 169
Sucampo Pharmaceuticals, Inc. 170
Sun Pharma Advanced Research Company (SPARC) Ltd. 170
Suzhou Sirnaomics Biopharmaceuticals Co. Ltd. 170
Sylentis S.A. 170
SynCore Biotechnology Co., Ltd 170
Synovo GmbH 171
Tacere Therapeutics, Inc. 171
Tactical Therapeutics, Inc. 171
Taejoon Pharm Co., Ltd. 172
Taiwan Liposome Company Ltd. 172
TearScience®, Inc. 172
Teijin Pharma Limited 172
ThromboGenics NV 173
TLC Biopharmaceuticals B.V. 173
TOA EIYO LTD. 173
TopiVert Ltd. 173
TRACON Pharmaceuticals, Inc. 174
TRB Chemedica International S.A. 174
TxCell 174
UNIMED PHARMA, spol. s r.o. 175
UNITHER Pharmaceuticals 175
University of Nottingham 175
University of Santiago de Compostela 175
Valeant Pharmaceuticals International, Inc. 176
Valentia Biopharma S.L. 176
Venture Life Ltd 176
Vibalogics GmbH 177
VisionCare Ophthalmic Technologies. Inc. 177
VISIOTACT Pharma 177
Wellstat Ophthalmics Corporation 177
X-BODY Biosciences, Inc. 178
Xcovery Vision 178
Xediton Pharmaceuticals Inc. 178
XOMA Corporation 179
Youcare Pharmaceutical Group Co., Ltd. 179
ZeaVision®, LLC 179
Ziarco 179

References

List of Tables

Table 2.1: Clinical status for common therapies for wet AMD
Table 3.1 Platform specifications
Table 4.1: Platform specifications
Table 5.1: Targets and their clinical status
Figure 6.1: Targets and their clinical status
Table 7.1: Targets in clinical stages
Table 7.2: Therapeutic platform specifications
 
List of Figures

Figure 8.1: Areas of research
Figure 8.2: Ocular disorders of interest
Figure 8.3: Promising therapies for ocular diseases
Figure 8.4: Promising targets for ocular therapies
Figure 8.5: Challenges encountered

Published By: CHI Healthtech
Product Code: CHI Healthtech1033


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: